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Abstract
Background Standardised integration of productivity costs into health economic evaluations is hindered by equity and distri-
butional concerns. Our aim was to explore the distributive impact of productivity cost methodological variation, describing 
the consequences for different groups.
Methods 527 prostate cancer survivors (2–5 years post-diagnosis) completed questions on work patterns since diagnosis. 
Productivity loss, categorised into temporary/permanent absenteeism, reduced hours and presenteeism, were costed in €2012. 
Valuation approaches included the human capital approach (HCA) and the friction cost approach (FCA), with wage multi-
pliers (WM) applied in additional analyses. Both national and self-reported wages were used. Costs were compared across 
socio-demographic and economic characteristics using non-parametric tests.
Results The estimated base case (HCA, using national wages) total productivity cost was €44,201 per prostate cancer 
survivor. Permanent absenteeism accounted for the largest cost (€18,537), followed by reduced work hours (€11,130), pres-
enteeism (€8148) and temporary absenteeism (€6386). Alternative valuation estimates ranged from − 90%  (FCAnational wage: 
€4625) to + 82%  (HCAWMself-reported wage: €80,485) compared to the base case and were consistently higher for self-reported 
wages compared to national wages. Statistically significant differences in productivity cost were found across four of the six 
survivor socio-demographic and economic characteristics by valuation approach, despite no significant difference in their 
physical unit equivalents.
Conclusions Our results indicate that the distributional impact of productivity costs varies by socio-economic and demo-
graphic characteristics. We advocate that: productivity loss should be reported in physical units where possible; cost estima-
tion should be subject to sensitivity analysis, and only where this is not feasible, that the HCA and national wages be used 
to value productivity loss where equity concerns are paramount.
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Introduction
Allocation and rationalising decisions within healthcare 
are informed by the key economic principle of constrained 
optimisation/minimisation. The approach aims to maximise 
health benefits produced or minimise disease burden for a 
constrained healthcare budget in a resource-limited setting 
[1, 2] and, hence, offer guidance to decision makers in the 
prioritisation of interventions [3]. A key ethical consid-
eration underpinning assessment of interventions or health 
technologies is whether indirect costs of illness should be 
included amongst the effects of an intervention [4]. The 
answer, to some degree, rests on the choice of evaluation 
perspective.
National health economic evaluation guidelines differ in 
their guidance [5]. A narrow healthcare payer perspective 
excludes indirect productivity costs [5]. A societal perspec-
tive, in contrast, necessitates the incorporation of all costs 
and effects associated with the intervention, regardless of 
where they occur [5, 6]. It is argued that not accounting 
for both direct and indirect costs and effects could result 
in suboptimal resource allocation [7] and fail to meet the 
social welfare maximisation objective. However, the societal 
approach is not without criticism as many social welfare 
functions are predicated on Paretian criteria where optimal-
ity is biased towards maintenance of the status quo and is 
dependent on an optimal initial distribution of income [8]. 
The debate continues.
The effects from a health intervention generate positive 
externalities beyond those obtained by the individual includ-
ing enhancing the productive capacity of the economy. The 
individual gains from an intervention include improved 
health status, a satisfying return to a social role, and the 
potential to earn income again [4]. Production gains to the 
economy arise when individuals return to health and are able 
to resume work [9]. From a societal perspective, illness can 
lead to (1) an absence from work leading to a reduction in 
output and/or (2) a reduction in labour input while at work 
due to limitations caused by the illness. Absenteeism and 
presenteeism disrupt the productive capacity of the economy 
and create productivity losses that may extend into the future. 
Valuation of these losses generally necessitates the applica-
tion of a suitable wage to monetarise the time and effort lost 
from work, with appropriate discounting for future values. 
Despite the importance of potential productivity gains of 
treatment and other interventions [10, 11], economic assess-
ments have been slow to incorporate these in their incremen-
tal cost effectiveness ratios (ICERs) perhaps—in part—due 
to unresolved ethical concerns, or a lack of guidance and 
standardisation in the valuation methodology [5].
Valuation methods for productivity costs include, primar-
ily, the human capital approach (HCA) and the friction cost 
approach (FCA). Recent adjustments to these methods have 
included the application of wage multipliers (WM). Each 
approach has a different distributional effect on the derived 
productivity costs, but these have rarely been compared in 
the literature. From an ethical perspective, the disparate dis-
tributional effects present concerns.
It has been argued [12] that the inclusion of productivity 
costs in economic evaluations prioritise health interventions 
aimed at individuals who return to paid work over interven-
tions whose health benefits accrue to non-paid working or 
non-working individuals. Because paid income is the pri-
mary valuation device for all three valuation approaches, 
existing labour market discrepancies tend to be transposed 
directly into productivity cost estimates. Women, the elderly, 
the very young and some minority groups are discriminated 
against due to differences in labour market participation 
and compensation levels [13]. Compensation mechanisms 
or imputing implicit wages for non-paid individuals may 
overcome some of these issues, however, the problem of dis-
parate productivity levels across populations remains [12].
This paper estimates productivity costs in a group of 
working prostate cancer survivors using two different pri-
mary valuation methods: the HCA and the FCA, with both 
subsequently modified with WM. To illustrate the potential 
distributional consequences and their ethical implications, 
we explored the distributive impact of each approach accord-




A population-based sample of survivors of prostate cancer 
on the island of Ireland participated in the study [14]. This 
analysis focused on those survivors in the Republic of Ire-
land (RoI) who were between 2 and 5 years post-diagnosis 
and working at the time of diagnosis.
Briefly, potentially eligible survivors were identified 
from the cancer registries in Ireland. Following screening 
for eligibility by their general practitioners, 1229 survivors 
2–5 years post-diagnosis in ROI were sent a postal question-
naire to complete between April and September 2012. This 
questionnaire sought information on socio-demographic 
characteristics, employment status and absenteeism/presen-
teeism before and after their prostate cancer diagnosis. Data 
on the duration of time absent from work and presenteeism 
were self-reported.
817 survivors completed the questionnaire. After restrict-
ing to those either employed or self-employed at the time of 
cancer diagnosis, the analysis included 527 survivors.
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Defining productivity costs
Productivity costs can be defined as ‘costs associated with 
production loss and replacement costs due to illness, disability 
and death of productive persons, both paid and unpaid’ [11]. 
We focused on those productivity costs associated with pros-
tate cancer survivors in paid work only, at diagnosis, and val-
ued time lost because of their treatment and ongoing recovery.
The cost reference year was 2012, with future values dis-
counted by 5% as recommended by Irish Health Technology 
evaluation guidelines [15], and wage inflation accounted for 
by average wage growth of 1% extrapolated from the Struc-
ture of Earnings Survey: Hourly Earnings 2008–2012 (https 
://ec.europ a.eu/euros tat/web/labou r-marke t/metho dolog y).
Productivity cutoff age
Productivity costs for temporary and permanent absenteeism 
were followed to an assumed retirement age of 65. In the 
cases of presenteeism and reduced hours, where respondents 
indicated being in employment beyond the official 65 years 
age of retirement, productivity loss was valued up to age 70.
Components of productivity loss
Temporary absenteeism
Temporary absenteeism includes missed days from work and 
associated output loss due to a period of illness [16]. Missed 
days can occur due to attendance at medical appointments 
for diagnosis and treatment, or treatment side effects, which 
can be longer lasting. Participants were asked: “Did you 
take any time off work for your cancer treatment?”. If yes, 
participants were asked: “how long were you or have you 
been off work?”. We measured temporary absenteeism as 
the number of days absent from work due to the individual’s 
cancer multiplied by the reported average number of hours 
usually worked per day prior to diagnosis.
Permanent absenteeism
Permanent absenteeism arises when an employed individual 
takes early retirement due to illness. Participants were asked: 
“Have you returned to work?” and “If no, do you intend to 
return to work in the future?”. We calculated permanent absen-
teeism when a survivor indicated that they had not returned to 
work following their diagnosis, did not intend to return to work, 
and were below the age of 65 (statutory retirement age in 2012).
Reduced hours
Reduced hour costs refer to the output lost when individuals 
return to work following an illness but work fewer hours than 
pre-diagnosis. This may occur due to ongoing psychological 
or physical effects of the illness or its treatment. Participants 
were asked: “How many hours do you usually work per week 
now?”. We estimated reduced hours by computing the dif-
ference between the average hours worked following return 
to work and those worked prior to the illness, aggregated per 
year, and summed until retirement age, assuming reduced 
hours remain over this period.
Presenteeism
Presenteeism refers to the reduced intensity and/or quality 
of work while working due to health problems [17]. Our 
study employed a filter question asking respondents who 
had returned to work: “Was your work productivity in the 
last week impaired by your prostate cancer?”, and if so, by 
how much (on a scale of 0–100%, following previous studies 
[17]). Costs were computed based on the percentage reduc-
tion in productivity as a portion of the individual’s wage and 
aggregated until retirement. Impairment was assumed until 
retirement due to the average age of the sample (63 years 
of age), and the average number of years post-diagnosis 
(3.9 years) for respondents.
Valuation approaches
We applied two primary valuation approaches: the human 
capital approach (HCA) and the friction cost approach 
(FCA), with both approaches subsequently modified accord-
ing to wage multipliers (WM) in additional analysis.
HCA
The HCA measures production loss due to illness by the 
present value of all lost future earnings of the individual, 
with income used as a proxy for output loss, assuming firms 
employ workers at a rate directly proportional to their con-
tributions to the firm, or their marginal revenue product [5, 
13]. The potential productivity loss is followed until return 
to work at previous productivity levels or retirement age, 
whichever is appropriate. In the base case, we applied the 
national gross median wage  (HCAnational wage) for the male 
working population in 2012 to productivity loss (https ://
ec.europ a.eu/euros tat/web/labou r-marke t/metho dolog y). A 
second application of the HCA was based on self-reported 
wages  (HCAself-reported wage) from the questionnaire.
FCA
The FCA has been developed to measure actual rather than 
potential productivity loss [18, 19]. Assuming the existence 
of involuntary unemployment, and that ill workers can be 
replaced from a pool of unemployed workers, productivity 
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losses arise only during a limited friction period following 
which a firm’s output is assumed restored to its initial level 
[5]. Even where production is made up for by the ill worker 
upon return, or by colleagues, an assumed loss still occurs 
due to a loss of leisure time to make up for this lost work.
Friction costs were calculated by applying national male 
gross median wages  (FCAnational wage) for the working popu-
lation to temporary absenteeism, reduced hours, permanent 
absenteeism and presenteeism. Separate estimates were 
calculated using self-reported wages  (FCAself-reported wage) 
as per the HCA (and an additional scenario is provided in 
Supplementary Table 1 where the FCA is adjusted for both 
compensation mechanisms and wage multipliers).
Absences and presenteeism loss were capped at 
11.3 weeks (as previously used for Ireland [20]), follow-
ing which the productivity cost was assumed zero. The fric-
tion period is comprised of an average vacancy duration for 
positions in Ireland of 7.3 weeks based on the results of a 
nationally representative survey plus an additional 4 weeks 
to account advertisement of the new role following perma-
nent absenteeism and the duration necessary for the uptake 
of a position following a successful application [20]. A 
reduction in labour time is assumed to cause a less than 
proportional decrease in production. As no estimate of this 
value exists for Ireland, an elasticity factor of 0.8 has been 
applied to derived estimates following the most frequently 
cited elasticity value in the literature originating from the 
Netherlands [21].
Presenteeism costs do not constitute time away from work 
as such but the application of the FCA to presenteeism can 
be justified, since in a competitive market, any reduction 
in on the job productivity by a returning worker will have 
to be compensated for by either, a colleague (under the 
assumption of lost leisure time) through internal slack or 
the reorganisation of work or a temporary staff member, to 
return productivity to previous levels. Our method assumed 
that when presenteeism was indicated by a participant, it 
occurred directly upon return to work, occurred only once, 
and was compensated for by a firm following the friction 
period due to the employment of additional staff so that it 
reduced to zero thereafter.
Adjustment for WMs
Many tasks in the workplace of the modern economy are 
undertaken as part of a team [22]. The absence of an indi-
vidual due to illness therefore can impact on the timing and 
performance of work by other team members. These exter-
nality effects have been presented in the literature as wage 
multipliers which capture productivity losses in excess of 
the market wage. The size of the multiplier is, in addition, 
dependent on the degree of substitutability of workers in a 
team environment in the workforce and the sensitivity of 
output to deadlines. Where perfect labour substitutes are 
unavailable and where output is sensitive to timing, the pro-
duction loss following worker absence is greater than the 
wage rate [22]. Wage multipliers have therefore been devel-
oped to account for these negative work loss effects with a 
recent study estimating an average wage multiplier of 1.97 
for absenteeism across occupation types and 1.54 for chronic 
presenteeism [23].
We accounted for multiplier effects across all types of 
productivity loss by applying occupation-specific multiplier 
estimates (for both absenteeism and presenteeism) derived 
from a recent survey of managers in Sweden [23: please 
refer to this study for a full list of occupation-specific multi-
pliers] to our HCA productivity estimates based on national 
gross median male wages  (HCAWMnational wage) and sepa-
rately for self-reported wages  (HCAWMself-reported wage). In 
supplementary analysis, we also adjusted our FCA estimates 
with WM (Supplementary Table 2).
Statistical analysis
To assess the implications of each valuation approach across 
groups of workers, productivity cost totals were disaggre-
gated by four socio-demographic characteristics (age at diag-
nosis, highest level of education, marital status at diagnosis 
and whether the individual had children), and two economic 
characteristics—(employment status at diagnosis (employed 
versus self-employed) and receipt of social welfare payments 
at diagnosis).
Descriptive statistics were reported to summarize key 
categories of work-related productivity loss in their physi-
cal units (days absent from work, etc.) and in their mon-
etarised form for the two primary valuation approaches 
and the WM-adjusted alternatives. Productivity costs were 
compared across survivor socio-demographic and eco-
nomic groups using non-parametric statistical tests, since 
data were not normally distributed) (i.e., Mann–Whitney 
and Kruskal–Wallis tests). Statistical significance was set at 
p < 0.05 and two-sided tests were used throughout.
Results
Survivor characteristics
Table 1 presents an overview of survivor characteristics. 
The majority (71.4%) of prostate survivors were older than 
60 at the time of diagnosis (mean = 61) and the survey 
(mean = 63). Just over two-thirds were educated only up 
to secondary level. Most (85.8%) were married or cohabit-
ing at the time of diagnosis, had children (61.4%), were not 
claiming social welfare benefits (86.7%) and were employed 
(61.5%) rather than self-employed.
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Equivalent days lost from work
The largest number of days lost from work (mean = 188) 
was due to permanent absenteeism, as would be expected 
(Table  2). This is followed by temporary absenteeism 
(86 days), reduced hours (85 days equivalent) and presen-
teeism (68 days equivalent). These components total 427 
equivalent days on average lost from work due to cancer by 
employed or self-employed survivors.
Productivity costs
Estimated total and sub-total mean productivity costs are 
presented in Table 2. The base case  (HCAnational wage) esti-
mated total productivity cost was €44,201 per working 
prostate cancer survivor which equates to €104 per work 
day lost. Amongst individual productivity cost drivers, per-
manent absenteeism accounted for the greatest proportion 
of the base case (€18,537; 41.9%), followed by the cost of 
reduced work hours (€11,130; 25.2%), presenteeism (€8148; 
18.4%) and temporary absenteeism (€6386; 14.4%).
Productivity costs estimated according to the alternative 
valuation techniques using national wages deviated widely 
from the base case, ranging between − 89%  (FCAnational wage: 
€4625) and + 49%  (HCAWMnational wage: €65,764). When 
individual cost components were considered, this range 
was − 95%  (FCAnational wage presenteeism costs) to + 106% 
 (HCAWMnational wage reduced hours costs) of the base case.
Using self-reported survivor wages rather than gross 
national wages resulted in higher estimated productivity 
costs  (HCAself-reported wage: €53,678; + 21.4% compared 
to base case). This finding was consistent across esti-
mates  (FCAself-reported wage: €7840; + 69.5% compared to 
 FCAnational wage and  HCAWMself-reported wage: €80,485; + 22.4% 
compared to  HCAWMnational wage).
None of the valuation techniques ranked cost drivers 
equivalent to their physical unit ranking and the ranking 
varied by approach. In the base case, for example, tempo-
rary absenteeism fell from second ranked in physical units 
to fourth ranked in terms of cost. Reduced hours rose from 
third ranked to second, while presenteeism rose from fourth 
to third. Valuation approaches also differed in their rank-
ing of costs. For example, the HCAWM ranked the cost of 
reduced hours highest, while the FCA ranked temporary 
absenteeism costs highest.
Distribution effects of socio‑demographic 
and economic sample characteristics
Considering equivalent days lost, amongst the six tested var-
iables, age group alone emerged as statistically significant, 
with those aged up to 60 years reporting 608 days lost on 
average, compared to 304 for those aged 61 years and above 
(p < 0.001) (Table 3). This significant finding was repeated 
across all monetary valuation techniques applied. There was 
no significant difference in days lost by marital status, and 
this was also consistent across all approaches.
In the case of highest level of education, having children, 
social welfare payments and employment status at diagnosis, 
the results of significance testing were incongruent between 
physical and monetary measures. For each characteristic, at 
least one valuation technique (and in the case of social wel-
fare payments, three techniques) exhibited statistically sig-
nificant differences, where no such difference was reported 
for the physical days equivalent measure. In addition, sta-
tistical differences were twice as commonly found for self-
reported wage valuation approaches compared to national 
wage approaches (4 versus 2 outside of the base case).
Discussion
Monetary approaches to valuing work absence 
and presenteeism
The magnitude of estimated productivity costs can affect the 
size of an ICER in economic evaluations when included, and 
the resultant policy decision on a proposed health technol-
ogy intervention [10, 11]. A primary concern in their estima-
tion is the choice of translation metric from physical units 
into monetary values [19]. Our study revealed striking differ-
ences in derived productivity costs both by cost component 
and in aggregated form due to choice of valuation approach. 
Table 1  Summary of survivor characteristics
Characteristic No. %
Age at diagnosis
 Up to 60 141 28.6
 Over 60 352 71.4
Highest level of education
 Up to secondary 332 69.2
 Tertiary 148 30.8






In receipt of social welfare payments
 No 418 86.7
 Yes 64 13.3
Employment status at diagnosis
 Employed 303 61.5
 Self-employed 190 38.5
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Total summed productivity cost estimated ranged between 
− 90%  (FCAnational wage) and + 82% (HCAWM self-reported wage) 
compared to the base case  (HCAnational wage). Such large devi-
ations would equate to substantial differences when added to 
the direct costs associated with, in this case, prostate cancer 
treatment and would potentially alter the ICER result of an 
economic evaluation compared to a stipulated threshold. For 
example, our base case productivity costs of €44,201 are 3.2 
times the size of the estimated direct healthcare costs for 
prostate cancer from diagnosis up to 4 years post-diagnosis 
at €13,818 per patient in Ireland [24].
Interestingly, our results revealed that the valuation 
approach was not only important for the magnitude of total 
productivity costs estimated but also distorted the rank-
ing of individual cost components. For example, under the 
 HCA(national wage), permanent absenteeism emerged as the 
highest ranked monetary cost component, compared to tem-
porary absenteeism under the  FCA(national wage) and the cost of 
reduced hours when the HCA was modified by WM (under 
the  HCAWMnational wage). Researchers should be cognisant 
of this potential divergence when focusing on individual 
productivity cost components rather than aggregated totals. 
This finding rarely arises in the literature due to the limited 
number of productivity components usually estimated and 
the lack of reporting of productivity loss in physical units for 
comparative purposes. More studies are required to explore 
this divergence across other population groups and cancers 
types.
Recent research [25] has highlighted the impact of dif-
ferent wage estimation approaches on productivity loss 
estimation by focusing on the use of average gross national 
mean wages versus age-specific wages. The findings indi-
cated that gross average wages overestimated lifetime pro-
ductivity loss for younger individuals affected by illness, 
but underestimated losses during the prime working age. 
Our study extended that analysis to compare productivity 
costs estimated using gross national wages to self-reported 
wages. Gross wages in this case cover remuneration in cash 
paid during the reference year before any tax deductions and 
social security contributions payable by wage earners and 
Table 2  Mean productivity costs per working prostate cancer survivor (€2012) and subcomponent costed by HCA, HCAWM and FCA
HCA human capital approach, HCAWM human capital approach adjusted for wage multipliers, FCA friction cost approach
Productivity cost categories Physical units (days 
or days equivalent)
Rank of cost 
component
Base case: HCA 
national wage (€)










Cost of temporary absenteeism 86 2 6386 4 6893 4 7.9
Cost of permanent absenteeism 188 1 18,537 1 23,778 1 28.3
Cost of reduced hours 85 3 11,130 2 15,128 2 35.9
Cost of presenteeism 68 4 8148 3 7879 3 − 3.3






































































11,829 4 45.2 11,502 4 41.2 380 4 − 95.3 373 4 − 95.4
Summed 
total
65,764 48.8 80,485 82.1 4625 − 89.5 7840 − 82.3
1405Variation in the methodological approach to productivity cost valuation: the case of prostate…
1 3
retained by the employer [https ://ec.europ a.eu/euros tat/stati 
stics expla ined/index .php/Gloss ary: Structure_of_earnings_
survey_(SES)]. To enhance comparability, self-reported 
wages from our survey, which were collected in net wage 
form using the question “Immediately before your diagno-
sis, what was your weekly take home pay?” followed by ten 
potential ranges, were modified to their gross sum based 
on the specifics of the Irish tax system and social welfare 
system. Deviations between wage rates in this study should 
therefore be based on the sample of wage earners included, 
rather than wage-based definition differences.
The impact of using self-reported wages to monetarise 
days lost from work increased the derived productivity cost 
estimate ranging from + 21% for  HCAself-reported wage to + 70% 
for  FCAself-reported wage, a result consistent across all produc-
tivity cost components and valuation types. Consequently, 
the use of self-reported wage data appears insensitive to 
valuation approach and results in higher monetary values, 
compared to gross wage equivalents. Key sample character-
istics such as an older age distribution of prostate cancer sur-
vivors at diagnosis compared to the average member of the 
working population upon whom national average wages are 
based, and a higher socio-economic status for prostate can-
cer survivors, may account for these results, but this finding 
requires further exploration across other population groups. 
Furthermore, the use of mean wages as opposed to median 
wages similarly increased derived productivity estimates, in 
this case between 14% (HCA and HCAWM) and 44% (FCA) 
compared to the base case (Supplementary Table 2).
The inclusion of presenteeism as a distinct component of 
productivity costs has been shown to represent a significant 
portion of the total societal costs associated with certain 
diseases [26]. A lack of consensus exists though on the most 
appropriate approach to measuring and valuing presenteeism 
costs in the literature. This can impact on the comparability 
Table 3  Significance results of non-parametric tests for differences in median total productivity costs by valuation approach based on socio-
demographic and economic sample characteristics
Statistical significance: *p < 0.05, **p < 0.01, ***p < 0.001






HCASelf-reported wage HCAWMnational wage HCAWMself-reported wage FCAnational wage FCASelf-reported wage
Age group  
(p value)
0.000*** 0.001** 0.000*** 0.000*** 0.000*** 0.011* 0.001**
 Up to 60 60 8614 12,000 15,371 21,000 4752 4800
 Over 60 26 2970 3671 7248 7070 2376 2304
Education level 
(p value)
0.214 0.474 0.959 0.505 0.887 0.035* 0.861
 Up to second-
ary
50 6683 6000 12,520 10,708 4519 2838
 Tertiary 35 3713 4731 8094 10,434 2838 2044
Marital status 
(p value)
0.406 0.948 0.676 0.963 0.653 0.919 0.311
 Married/
cohabiting
45 5941 6308 11,881 11,631 3904 3044
 Other 26 3910 2633 8094 5450 1880 1262
Children  
(p value)
0.205 0.101 0.077 0.089 0.065 0.046* 0.062
 No 20 2970 3548 5614 5925 2128 1716
 Yes 50 5941 8467 13,738 15,015 4671 3529
Social welfare 
(p value)
0.172 0.133 0.049* 0.107 0.033 0.125 0.035*
 No 16 743 335 1240 941 934 229




0.166 0.188 0.088 0.227 0.092 0.135 0.007**
 Employed 48 6312 7269 12,297 13,873 4117 3342
 Self-employed 33 2970 3318 6237 6380 2376 1664
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of derived results across studies and hinder the inclusion of 
presenteeism costs in economic evaluations.
Our approach to measurement followed an indirect quan-
tification method whereby respondents were asked their per-
ceived overall estimate of how much the illness hindered 
their work on a 0–100% scale. This resulted in an estimated 
presenteeism cost of €8148 or 18% of total costs in the base 
case, the absence of which would have resulted in a consid-
erable underestimation of the productivity costs associated 
with prostate cancer. Other measurement approaches exist 
including the direct approach which asks respondents about, 
for example, low concentration levels or feeling fatigue at 
work and the duration of these episodes [26] and a further 
approach using a comparison of respondent perceived work 
performance to that of a colleague in a similar role. Never-
theless, the indirect approach is the most widely used in the 
literature [26].
An additional finding that adds to the extant productiv-
ity cost literature includes the adjustment of presenteeism 
costs for multiplier effects. It has been argued that wages 
underestimate the productivity loss resulting from absence 
from work [23] due to job-specific characteristics such as 
teamwork, the ease of substitution of workers and the time 
sensitivity of output. A recent review [17] observed that 
these wage multiplier effects have not been previously used 
to adjust presenteeism costs. Our estimates revealed that the 
application of occupation-specific presenteeism multipli-
ers resulted in an increase in costs to between 41 and 45% 
compared to the base case  (HCAnational wage) and so carry 
the potential to significantly impact derived estimates. In 
addition, our study reported estimates of presenteeism cost 
according to the FCA which has been underreported in the 
literature to date [17]. In our study, the estimates for FCA 
presenteeism costs amounted to 5% of the base case equiva-
lent estimates and 8% of total summed FCA costs.
Productivity cost valuation and its distributional 
impact
A major reason for excluding productivity costs from eco-
nomic evaluations to date, beyond issues over methodologi-
cal standardisation, is related to ethical concerns [5]. It is 
argued that incorporating productivity gains into economic 
evaluations will favour interventions targeted at those that 
are employed over those not reimbursed by the market, the 
unemployed and retirees [12]. However, as stated by Krol 
et al. [5], such distributional consequences do not justify 
their exclusion. More so, it is a reason for researchers and 
policymakers to be cognisant of the implications of includ-
ing productivity costs/gains in economic evaluations, the 
manner in which the selection of valuation approach can 
affect derived estimates and, crucially, being transparent 
about the resulting equity implications of these.
The current study focused on the distributional conse-
quences of alternate productivity cost valuation techniques 
for a relatively homogenous group of employed and self-
employed prostate cancer survivors. While equity concerns 
have traditionally focused on working versus non-working 
cohorts, the distribution of productivity costs may also vary 
across groups depending on methodological approach. We 
have shown that this is indeed the case, and heterogeneity 
in income levels, age and education caused equity concerns 
and distributional issues.
All but two socio-demographic and economic character-
istics included in the study (age and marital status) produced 
statistically significant variations in our estimated productiv-
ity costs depending on the valuation technique applied. Only 
the base case  HCAnational wage monetary valuation approach 
produced an equivalent distribution of productivity costs 
to their physical unit measures (days equivalent). All other 
valuation approaches, using both national wages and self-
reported wages, produced significant differences in produc-
tivity cost by survivor characteristic indicating variation in 
distributional impact. Indeed, the use of self-reported wage 
data rather than national wages tended to exacerbate this 
effect and resulted in four significantly different cost results 
compared to two for national wages amongst our approaches. 
Therefore, as valuation methods begin to resemble more 
closely real-world labour market conditions at a micro level, 
the associated distributional issues present there are trans-
posed onto derived productivity costs resulting in greater 
variability by survivor characteristic.
A trade-off appears to exist between greater accuracy 
based on real-world labour market data to estimate produc-
tivity costs specific to the cohort under study (a key effi-
ciency concern), and the increased distributional concerns 
that arise (a key equity concern). We agree with Zhang et al. 
[27] and recommend that where researchers use productiv-
ity costs for health care decision making, they should also 
report the costs in their physical unit form for transparency, 
so that alternative valuation approaches may be applied 
where necessary and equity issues derived from these are 
explored through sensitivity analysis. Greater transparency 
thus constitutes a key approach moving forward in the pro-
ductivity cost estimation literature, where efficiency versus 
equity concerns can be judged on a case-by-case basis by the 
appropriate decision makers based on personal preference 
sets and national-specific welfare functions where appro-
priate. Where sensitivity analysis of alternative valuation 
approaches cannot be undertaken, due to time or data con-
straints, based on the results here, we would recommend the 
selection of the HCA and national wages to value productiv-
ity loss to minimise distributional issues where equity is a 
key concern.
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Strengths and limitations
Our study adds to the literature by indicating the impact 
of survivor characteristics on productivity costs using 
alternative estimation approaches indicating a distinct effi-
ciency–equity trade-off in current methodological practice. 
We also encompass a broad range of productivity types 
(absenteeism, permanent absenteeism, reduced hours and 
presenteeism) in the study, in addition to applying the most 
up to date estimates for WM.
While the use of a sample of prostate cancer survivors 
was advantageous in terms of the homogeneity of the cohort 
where distributional concerns by characteristic would not be 
perceived as substantial a priori, this decision limited our 
choice of relevant testable demographic variables, namely 
gender, which would have been of interest in the analysis. 
Responses to our questionnaire were provided, on average, 
3.9 years post-diagnosis. This may have caused issues with 
recall which may have impacted on our results. In addition, 
this may explain the small percentage of respondents who 
reported presenteeism (13%).
Our estimates of wage multipliers by occupation were 
derived from a Swedish study, where labour market con-
ditions may not be perfectly matched to Irish labour mar-
ket conditions, however, no estimates of multipliers exist 
for Ireland currently. Estimates derived for the FCA are 
also dependent on the extant labour market conditions in a 
country and variation in the friction period can occur due 
to deviations in the unemployment rate and the vacancy 
rate. Specifically, shorter friction periods are predicted as 
unemployment rates rise and longer periods are predicted 
from increasing vacancy rates. This issue is explored further 
for Ireland in [20]. Variation in labour market conditions 
between the estimation of the friction period for Ireland used 
in this study (2006) and the analysis year (2012) may hinder 
the accuracy of the results. This, however, is a general limi-
tation of the FCA approach and not specific to this study.
There exists an ongoing conflict between the FCA and the 
application of WM where absenteeism is assumed to result 
in a less than proportionate decrease in production accord-
ing to the FCA compared to a greater than proportionate 
increase for WM. This conceptual incongruence is beyond 
the current study to assess but remains an interesting field 
of further study. We have, however, attempted to account for 
both compensation mechanisms and wage multipliers in the 
FCA in this study following [28] and placed the results of 
this in Supplementary Table 1.
Finally, in the base case, we applied the national gross 
median wage to estimate productivity losses. This may have 
led to a degree of overestimation of productivity costs com-
pared to the use of age-specific wages [25]. To account for 
this, we also applied survey specific (and thus age-specific 
sample wages) in a second application.
Conclusion
Equity and distributional concerns remain a major hindrance 
to the integration of productivity costs into health economic 
evaluations. This study shows that striving for greater accu-
racy in the efficiency of productivity cost estimates may 
come at the expense of equity and distributional concerns. 
Derived productivity cost estimates varied depending on the 
selection of valuation approach and the underlying socio-
demographic characteristics of the sample. We advocate 
that productivity loss should be reported in physical units 
where possible, cost estimation should be subject to sensi-
tivity analysis in terms of approach, and where this is not 
feasible, we recommend selection of the HCA and national 
wages to value productivity loss where equity as opposed to 
efficiency concerns are paramount.
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